Navigation Links
CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
Date:10/25/2007

- Significant anti-tumor activity of combination IV belinostat in ovarian

cancer reported - - Oral belinostat demonstrated to be safe and well-tolerated in Phase I -

- Presentation of results from two NCI-sponsored clinical trials - - CuraGen to provide a clinical update conference call today at 5:00 p.m.

Eastern Time -

BRANFORD, Conn., Oct. 25 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today that four posters discussing clinical trial results with belinostat were presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA. Data reported included Phase II clinical trial results on intravenous belinostat in combination with carboplatin and paclitaxel for relapsed ovarian cancer, Phase I safety and dose-escalation results for oral belinostat, and data from two NCI-sponsored clinical trials including Phase II results evaluating intravenous belinostat monotherapy for the treatment of ovarian cancers and Phase I results of belinostat in combination with bortezomib for advanced tumors.

CLN-8: Phase II Multicenter Trial of Belinostat (PXD101) in Combination with Carboplatin and Paclitaxel (BelCaP) for Patients with Relapsed Ovarian Cancer

Phase II results for CLN-8 were presented by Neil J. Finkler, MD, FACOG, FACS, Investigator and Director of the Gynecologic Oncology Program at Florida Hospital Cancer Institute in Orlando. At the time of the poster presentation, data were available on 23 patients including efficacy data for 16
'/>"/>

SOURCE CuraGen Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for Belinostat
2. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
3. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Sygnis Pharma AG announces date for presentation of clinical results
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009).../PRNewswire/-- ChemoCentryx,Inc.,announcedtodayth...(theProspectiveRandomizedOralTherapyEvaluationinCr...ientswithmoderate-to-severeCrohn,sdiseasedemonstra...lityprofile.Thestudydemonstratedevidenceofclinical...a70-pointdecreaseintheCrohn,sDiseaseActivityIndex(...
(Date:11/24/2009)...wswire-FirstCall/--Vermillion,Inc.(VRML)(PinkSheet...ationandDisclosureStatementtoday,November24,2009,w...elaware.AhearingtoconsiderapprovaloftheDisclosureS...thehearingontheconfirmationofthePlanscheduledforJa...llclaimsinfull.ThePlanisexpected,ifapproved,toallo...
(Date:11/24/2009).../--Accumetrics,Inc.,aprivately-helddeveloperandmar...sy-to-usediagnosticsystemformeasuringanindividual,...174;andaspirin),announcedtodaythatTimothyI.Still,P...hiefFinancialOfficerofAccumetrics,willbepresenting...hCareConferencebeingheldinNewYorkCityonDecember1-2...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Vermillion Files Plan of Reorganization 2Vermillion Files Plan of Reorganization 3Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference 2Seizures Not Epilepsy Itself May Raise Birth Risks 54172 1Seizures Not Epilepsy Itself May Raise Birth Risks 54172 2Oral Drug Ups Survival in Advanced Prostate Cancer Cases 54170 1Oral Drug Ups Survival in Advanced Prostate Cancer Cases 54170 2For Macho Men Doctor Visits Are Less Likely 54168 1For Macho Men Doctor Visits Are Less Likely 54168 2
...A -- (MARKET WIRE) -- June 14,2007 -- Targeted Ge...ng data from the dose escalation arm of the ongoin... with inflammatory,arthritis. Philip J. Mease, M.D...ton School of Medicine, chief of rheumatology,clin...icing,physician with Seattle Rheumatology Associat...
...PRNewswire/ -- Prolexys,Pharmaceuticals and announ...of the selective small molecule anti-tumor agent,...,s,chemi-proteomics technology to understand the m...published in the June 14, 2007 issue,of the journa...l,voltage- dependent anion channels (VDACs) -- a n...
Other Medicine Technology:Targeted Genetics Reports Inflammatory Arthritis Clinical Data at,European Rheumatology Conference 2Targeted Genetics Reports Inflammatory Arthritis Clinical Data at,European Rheumatology Conference 3Targeted Genetics Reports Inflammatory Arthritis Clinical Data at,European Rheumatology Conference 4Targeted Genetics Reports Inflammatory Arthritis Clinical Data at,European Rheumatology Conference 5Targeted Genetics Reports Inflammatory Arthritis Clinical Data at,European Rheumatology Conference 6Prolexys Pharmaceuticals and Columbia University Researchers,Publish Study on Anti-Tumor Properties of a Selective Small,Molecule Anti-Tumor Agent With Novel Mechanism of Action 2Prolexys Pharmaceuticals and Columbia University Researchers,Publish Study on Anti-Tumor Properties of a Selective Small,Molecule Anti-Tumor Agent With Novel Mechanism of Action 3
(Date:11/25/2009)...le in French . , , Montreal, November 25, 20...he marketplace, thanks to a new partnership betwee... and Cognitive Sensing Inc. (CSI), a privately own...lor, which commercializes discoveries from the Uni... and CSI have announced the signature of a license...
(Date:11/25/2009)...ans at UT Southwestern Medical Center soon will be...eathing in patients with upper spinal-cord injurie...independently. , UT Southwestern University Hos...exas and one of 25 in the country currently equipp...gm Pacing System. , The device is designed to gi...
(Date:11/25/2009)...uccess for patients with liver lesions, researcher... News) -- Adding the drug cetuximab to neoadjuvant... of successful surgery in colorectal cancer patien...esearch suggests. , , Tumors spread to other p...h colorectal cancer. Most commonly, the cancer spr...
(Date:11/25/2009)...ndly ways to enjoy festive feasting , , ... the five-week holiday smorgasbord from Thanksgivi...the added pounds you,ll have to sweat off come Jan...ition experts, to enjoy holiday eating and make ..., It,s all about devising a strategy and thinking ...
(Date:11/25/2009)...llege teaches students to use natural treatments t... Burnaby, BC (Vocus) November 25, 2009 ...he standard, effective treatments in the fight aga...dicine to help them cope with the side effects of ...f cancer patients using acupuncture and herbal med...
Breaking Medicine News(10 mins):Health News:Univalor and Cognitive Sensing Inc. to commercialize 4 University of Montreal discoveries 2Health News:New device implanted by surgeons help paralyzed patients breathe easier 2Health News:Cetuximab Helps Treat Colorectal Cancer 2Health News:Holiday Eating Without the Guilt -- or the Pounds 2Health News:Holiday Eating Without the Guilt -- or the Pounds 3Health News:Holistic and Western Medicine Combined Can Fight Cancer 2
... a cancer-fighting tomato. The supermarket giant h... is lycopene-rich to the tune of almost twice that...hemical that gives red color to the tomatoes and i...ngs of tomatoes per week decreased the risk of dev...
...chers have found that shock wave lithotripsy, whic...ed the risk of diabetes and also hypertension in l... to the intensity of the treatment and quantity of...p an impassable kidney stone into smaller, sandlik...
...New York are sometimes good from far but far from ... opportunity and over all a good life// , might no...ents. According to a latest survey, New Yorke... one out of seven adults complained of being emoti...
...at about1.4 million Australians have diabetes. New... the number of people with diabetes// over the pas...nd the economy to take some aggressive action agai...e diet and lifestyle factors. About 200 diabetes e...
...ll study conducted by researchers at the Texas-bas...ironmental Medicine it was found// that high level...amples from women who had silicone gel-filled brea...r their safety. Now the findings represent the lat...
...h most abundantly produced chemical in the United ...eum. It is a colorless or light yellow liquid at r...ly flammable. It is formed from both natural proce...mercially on account of the many valuable compound...
Other Medicine News:Health News:Shock Wave Therapy Increase The Risk Of Diabetes 2Health News:Shock Wave Therapy Increase The Risk Of Diabetes 3Health News:Its High Time the Australian Government Takes Steps against Diabetes 2Health News:The Multi-Faceted Chemical Benzene 2Health News:The Multi-Faceted Chemical Benzene 3Health News:The Multi-Faceted Chemical Benzene 4Health News:The Multi-Faceted Chemical Benzene 5Health News:The Multi-Faceted Chemical Benzene 6
...tact lenses used for corneal refractive therapy, a... (myopia). The patient wears the lenses overnight ...ing the day, nearsightedness is corrected or great... lenses apply slight pressure to the center of the...
...e major challenges to operating your own Nuclear C...cedure includes:, NRC, state and other licensure...echnologist., New, dual head nuclear imaging camer...ure supplies, including pharmaceuticals., Radiatio...
... 330 ,Straight, ,Konan realized an ideal coa...een lenses for observation. This illumination shou...aryngology, ,Konan offers what no other conven...nction (1:3) and a clear image at every possible m...
...xperienced provider of mobile catheterization serv...bile laboratories serving hospital networks are mo...o another in a particular hospital network or geog...ped and operated by MedCath medical technicians an...
Medicine Products: